OVAS - OvaScience, Inc.

YHD - YHD Delayed Price. Currency in USD
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (3Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • Waltham biotech OvaScience shuts down as reverse merger closes
    American City Business Journals7 months ago

    Waltham biotech OvaScience shuts down as reverse merger closes

    As part of the deal with Millendo Therapeutics, OvaScience's remaining eight employees will be laid off and the company's Waltham office will close.

  • OvaScience shareholders sue to stop Millendo merger
    American City Business Journals7 months ago

    OvaScience shareholders sue to stop Millendo merger

    A group of OvaScience stockholders are alleging in a series of lawsuits that the struggling fertility startup failed to disclose important information about the merger process, which the company denies.

  • PR Newswire8 months ago

    INVESTOR ALERT: Monteverde & Associates PC Is Investigating The Acquisition Of OvaScience, Inc. Scheduled For A Shareholder Vote On December 4, 2018 - OVAS

    NEW YORK , Nov. 16, 2018 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...

  • Benzinga9 months ago

    The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 1) Gritstone Oncology Inc (NASDAQ: GRTS ) Repligen Corporation ...

  • Business Wire9 months ago

    OvaScience and Millendo Therapeutics Provide Update on Merger Agreement and Financing

    OvaScienceSM (OVAS) and privately-held Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases, today announced that the companies have updated the terms of their merger agreement and increased the size of the associated financing, strengthening the position of the combined company. Great Point Partners has joined the previously-disclosed investor syndicate, which includes New Enterprise Associates, Frazier Healthcare Partners, and Roche Venture Fund, among others, bringing the total expected proceeds of the financing to approximately $50 million in the combined company, at the same valuation as the merger.

  • Associated Press11 months ago

    OvaScience: 2Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of 22 cents per share. Losses, adjusted for restructuring costs, were 14 cents per share. The infertility treatment company posted revenue of ...

  • Business Wire11 months ago

    OvaScience Reports Second Quarter 2018 Financial Results and Provides Strategic Alternatives Update

    OvaScienceSM , a company focused on developing novel treatments for women and couples struggling with infertility, today reported financial results for the second quarter ended June 30, 2018 and provided an update on its review of strategic alternatives.

  • Business Wire11 months ago

    OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company

    OvaScienceSM (OVAS) and privately-held Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases, announced today that they have entered into a definitive agreement under which OvaScience will merge with Millendo in an all-stock transaction. The merged company will focus on advancing Millendo’s pipeline of distinct and transformative treatments for orphan endocrine diseases. Upon shareholder approval, the combined company is expected to operate under the name Millendo Therapeutics and trade on the Nasdaq Capital Market under the ticker symbol MLND.